Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key secondary endpoints INDIANAPOLIS , April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent of patients with